Skip to main content

Table 5 Base case results for the treatment of rheumatoid arthritis in Spain over a lifetime horizon (45 years)

From: Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain

 

Mean costs (€)

Difference in costs vs CZP (€)

Mean QALY

Difference in QALYs vs CZP

ICER vs CZP

Combination therapies

CZP + MTX

140,971

0

6.578

0

ADA + MTX (every 2 weeks)

139,148

1823

6.430

0.148

€12,346

ADA + MTX (weekly)

164,741

−23,770

6.430

0.148

CZP dominant

ETA + MTX

141,197

−226

6.462

0.116

CZP dominant

IFX (3 mg/kg) + MTX

136,961

4010

6.318

0.260

€15,414

IFX (5 mg/kg) + MTX

152,561

−11,590

6.318

0.260

CZP dominant

Monotherapies

CZP

134,792

0

6.416

0

ADA (every 2 weeks)

136,745

−1953

6.216

0.200

CZP dominant

ADA (weekly)

156,223

−21,431

6.216

0.200

CZP dominant

ETAa

135,459

667

6.492

0.076

€8,778a

  1. ADA adalimumab, CZP certolizumab pegol, ETA etanercept, ICER incremental cost-effectiveness ratio, IFX infliximab, MTX methotrexate, QALY quality-adjusted life years
  2. aIncremental Analysis is for ETA versus CZP and not the other way round